Navigation Links
VisionGate Uses $2.6 Million NIH Grant to Achieve Full Automation of Cell-CT™ 3D Imaging System for Early Diagnosis of Cancer
Date:1/6/2012

sion of our first applications to the Food and Drug Administration (FDA) later this year for regulatory review of LuCED."

In a July 2011 presentation at the International Academy for the Study of Lung Cancer's 14th World Conference on Lung Cancer, VisionGate showed how LuCED and the Cell-CT platform can accurately detect cancer cells in sputum samples from individuals at high risk of lung cancer.

Scarlett Spring, President of VisionGate, noted, "Achieving full automation of the Cell-CT platform is another on-time milestone in our plans to file for regulatory approval of the LuCED test during 2012.  It also complements our recently announced strategic partnerships for clinical assessment of the LuCED technology used adjunctively to reduce the high rate of false positive cases that result from x-ray CT lung cancer screening.  We expect these partnerships will provide valuable data to further advance our LuCED regulatory strategy."

LuCED and the Cell-CT platform produce detailed 3D images of cells in sputum, which the system automatically analyzes to identify key features, or biosignatures, associated with potential malignancy.  The analysis yields a score that indicates whether or not cancer cells are present.  The Cell-CT system produces strikingly clear and comprehensive 3D images of the cells, enabling extremely accurate classifications.  LuCED is initially being developed for use in conjunction with x-ray CT screening, which has been shown to reduce lung cancer deaths in high-risk individuals, but which also has a high rate of false positive results.  LuCED is expected to greatly reduce the incidence of false positives, potentially enabling the approach to be used for cost-effective lung cancer screening on a mass scale.

"The Cell-CT 3D imaging system could be a valuable tool for early detection of lung cancer, when the disease is potentially curable," said David Yankelevitz, MD, Professor of Radiology a
'/>"/>

SOURCE VisionGate, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. VisionGate Closes $2 Million Financing and Announces Collaboration to Evaluate Its 3D Cell Imaging Platform for Early Lung Cancer Detection
2. Vermillion Sharpens Focus and Streamlines Operations in 2012
3. Bionovo Announces $5 Million Financing
4. Amsterdam Molecular Therapeutics Announces € 2.5 Million Equity Raise
5. Netsmart Clients to Receive Nearly $2 Million in Meaningful Use EHR Incentive Payments
6. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
7. Fox Insurance Company Awarded $3.3 Million in Arbitration Against Former Pharmacy Benefit Manager
8. CeNeRx BioPharma Completes $4.85 Million Financing
9. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
10. Aratana Therapeutics Completes $15 Million Series B Financing
11. InnoPharma Completes $15 Million Series A Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Pipette.com announces their Holiday in the ... their #HolidayInTheLab pictures for a chance to win pipette-themed ... those struggling to think of a holiday gift for ... Lab Contest provides the ideal holiday presents. The #HolidayInTheLab ... pictures of their chemistree, holiday sweaters, as well as ...
(Date:12/24/2014)... LOUIS , Dec. 23, 2014 ... today that the waiting period under the Hart-Scott-Rodino ... the acquisition expired on December 22, 2014, thereby ... review requirement for the acquisition of the Company ... U.S. antitrust clearance satisfies another condition to closing ...
(Date:12/22/2014)... Md. , Dec. 22, 2014 /PRNewswire/ ... SYN), a developer of pathogen-specific therapies for ... on protecting the microbiome, today announced positive ... Phase 1a clinical trial of SYN-004, the ... prevention of Clostridium difficile (C. difficile) ...
(Date:12/22/2014)... 22, 2014  ( www.competitivehealth.com ) — Competitive Health ... bill review and advocacy service, has signed an agreement ... Savings discount health services marketplace. 63% of ... than they expected to pay. As part of an ... WellCard Savings is pleased to offer medical bill review ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
... Pa. and WEYBRIDGE, England, Dec. 6, 2010 ... Idis, the global leader in developing long-term strategic ... two companies have partnered to facilitate access to ... (NPP).  ViroPharma,s NPP, developed and managed by Idis, ...
... ANGELES, Dec. 6, 2010 Todd Hutchings has assumed ... Practice Group.  Peter Levin, who led the practice, will ... recruiting CEOs and C-Level executives. In his ... core client relationships, working with boards and providing the ...
... Dec. 6, 2010 Cell Therapeutics, Inc. ("the Company") ... of study ("EOS") follow up results from the Company,s ... basis for the Company,s recent Marketing Authorization Application (the ... ("EMA"). The end-of-study results showed continued improvement ...
Cached Biology Technology:ViroPharma Incorporated and Idis Partner to Facilitate International Access to Certain ViroPharma Therapeutics Through Named Patient Program 2ViroPharma Incorporated and Idis Partner to Facilitate International Access to Certain ViroPharma Therapeutics Through Named Patient Program 3Egon Zehnder International Names Todd Hutchings to Lead Life Sciences Practice Group 2New Pixantrone Data Presented at Meetings at American Society of Hematology Conference 2New Pixantrone Data Presented at Meetings at American Society of Hematology Conference 3New Pixantrone Data Presented at Meetings at American Society of Hematology Conference 4New Pixantrone Data Presented at Meetings at American Society of Hematology Conference 5New Pixantrone Data Presented at Meetings at American Society of Hematology Conference 6
(Date:12/10/2014)... December 9, 2014   ... Platform   Jifflenow, ... scheduling solutions for business-to-business (B2B) events, today announced ... in mobile near-field communication (NFC), Bluetooth low energy ... (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate ...
(Date:12/4/2014)... PALM BEACH GARDENS, Fla. , Dec. 3, ... identity management solutions, today announced that its DigitalPersona ... 4500 fingerprint readers have been deployed throughout ... Carolina , South Carolina ... network headquartered in Southern Pines, North ...
(Date:11/21/2014)... , November 18, 2014 ... Systems Market by Systems (Video, RFID, Access Control, Intrusion ... Factories, Hotels, Banks, Government), Component Service Geography - Global ... Systems Market is projected to be around $25 Billion ... by 2020, growing at a CAGR of 8.69%. ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... Georgia Institute of Technology have developed a strategy to ... prevent the pollutant from finding its way from a ... a zero emission car, and a transportation system completely ... dioxide emissions from large-scale sources such as power plants ...
... developing is a goal of Raphael Kopan, Ph.D., professor ... School of Medicine. The moss plant (Physcomitrella patens) ... Spencer T. Olin Professor and chair of the WUSTL ... toward that goal. Heres how. The gene ...
... in the media, and recently, in our daily lives, ... is affecting global climate change. Studying just how carbon ... one Northwestern University professor is doing his part by ... associate professor of civil and environmental engineering in the ...
Cached Biology News:Carbon capture strategy could lead to emission-free cars 2Carbon capture strategy could lead to emission-free cars 3Carbon capture strategy could lead to emission-free cars 4Moss protein plays role in Alzheimer's disease 2Moss protein plays role in Alzheimer's disease 3Moss protein plays role in Alzheimer's disease 4Studying rivers for clues to global carbon cycle 2Studying rivers for clues to global carbon cycle 3
Rabbit polyclonal to Xanthine Oxidase (HRP) ( Abpromise for all tested applications). Antigen: Xanthine Oxidase (from Bovine Buttermilk) Entrez Gene ID: 7498 Swiss Protein ID: P47989...
Phospho- (Ser) 14-3-3 Binding Motif (4E2) Mouse mAb...
Drugs and NO-drug Rat Anti-conjugated Acetyl Salicylic Acid Polyclonal Antibody...
GBL Antibody...
Biology Products: